Zacks Research Issues Negative Estimate for Qiagen Earnings

Qiagen N.V. (NYSE:QGEN) – Analysts at Zacks Research cut their Q4 2025 earnings estimates for Qiagen in a research report issued on Thursday, January 22nd. Zacks Research analyst Team now anticipates that the company will post earnings of $0.62 per share for the quarter, down from their prior estimate of $0.62. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q3 2026 earnings at $0.67 EPS, Q4 2026 earnings at $0.63 EPS, Q1 2027 earnings at $0.68 EPS, Q2 2027 earnings at $0.70 EPS and Q3 2027 earnings at $0.72 EPS.

Other research analysts have also recently issued research reports about the company. Citigroup cut Qiagen from a “buy” rating to a “neutral” rating and cut their price target for the stock from $57.89 to $52.63 in a research note on Thursday, December 11th. Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. UBS Group reaffirmed a “neutral” rating on shares of Qiagen in a research report on Wednesday. Barclays reissued an “overweight” rating and set a $57.89 price target (up previously from $55.79) on shares of Qiagen in a research report on Monday, December 15th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $53.04.

Qiagen Stock Performance

NYSE:QGEN opened at $55.56 on Friday. The firm has a 50-day moving average of $48.88 and a two-hundred day moving average of $49.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. The stock has a market cap of $11.73 billion, a P/E ratio of 28.68, a PEG ratio of 2.54 and a beta of 0.66. Qiagen has a 1-year low of $39.61 and a 1-year high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The business had revenue of $532.58 million during the quarter, compared to analyst estimates of $525.68 million. During the same period last year, the business earned $0.60 EPS. The business’s revenue was up 6.2% on a year-over-year basis.

Hedge Funds Weigh In On Qiagen

A number of hedge funds have recently added to or reduced their stakes in the business. Boston Partners bought a new stake in Qiagen in the third quarter valued at $179,450,000. Norges Bank bought a new position in shares of Qiagen during the second quarter worth about $158,728,000. Dimensional Fund Advisors LP acquired a new stake in shares of Qiagen in the 3rd quarter worth about $58,079,000. Allianz Asset Management GmbH lifted its position in Qiagen by 366.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 994,697 shares of the company’s stock valued at $47,470,000 after purchasing an additional 781,561 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Qiagen by 117.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,252,948 shares of the company’s stock valued at $60,217,000 after purchasing an additional 675,498 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Zacks Research nudged its Q1 2027 EPS estimate up to $0.68 from $0.67, a small positive signal for near‑term earnings expectations that may be helping support the stock.
• Neutral Sentiment: Media pieces note that analysts are “conflicted” on Qiagen, highlighting mixed buy/hold/sell views rather than a consensus directional change; this increases focus and trading but doesn’t force a clear fundamental shift. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: A similar roundup notes mixed analyst views again (adds visibility and trading interest but not a unified directional signal). Analysts Conflicted on These Healthcare Names
• Negative Sentiment: Zacks Research lowered multiple quarterly EPS estimates (including Q3 2027 and Q4 2026) and trimmed near‑term forecasts overall — a signal that analysts see some softening in near‑term profit trends. Consensus full‑year EPS remains around $2.26, but the downward quarterly revisions are a near‑term negative for sentiment.
• Negative Sentiment: Deutsche Bank downgraded Qiagen, a direct negative from a major sell‑side firm that can pressure sentiment and weighing on shares despite the mixed analyst picture. Deutsche Bank downgrades Qiagen NV (QGEN)

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.